April 17, 2024
Nippon Shinyaku said on April 16 that it has filed for approval a pediatric indication of its oral pulmonary arterial hypertension (PAH) treatment Uptravi (selexipag) as well as a new formulation intended for children. The company submitted two applications the...read more